Daily ReportSep 9, 2026
Sepsis, September 9 edition
We read 40 papers and selected 3.
Summary
Today's most impactful sepsis research spans disease-stage-adaptive nanotherapy, a newly defined epigenetic–mitochondrial mechanism of sepsis-associated cognitive dysfunction, and population-level validation of hospital-onset bacteremia as a quality metric. Together, these studies advance therapeutic design, mechanistic understanding, and health-system measurement, although the therapeutic findings remain preclinical.
Research Themes
- Disease-stage-adaptive nanotherapy and immune reprogramming
- Epigenetic regulation of mitochondrial dysfunction in sepsis-associated encephalopathy
- Hospital-onset bacteremia as a health-care quality metric
Selected Articles
1. Disease-Stage Synchronized Nanozyme Therapy for Polymicrobial Sepsis through Adaptive Catalytic and Immune Reprogramming.
The authors developed MICP@HG, a pH-adaptive nanozyme that changes its function during sepsis progression. It promoted cuproptosis-like bacterial killing in acidic infectious environments, then shifted toward superoxide dismutase- and catalase-like antioxidant activity and macrophage reparative reprogramming as inflammation resolved. The platform eradicated multidrug-resistant bacteria, preserved organ function, produced complete survival in polymicrobial sepsis models, and generated vaccine-like trained immunity.
Impact: This study addresses a central limitation of sepsis therapy: the disease changes from pathogen-dominant inflammation to oxidative and immune dysfunction over time. Its temporally programmed therapeutic design represents a substantial conceptual advance beyond static antimicrobial or anti-inflammatory treatment.
Clinical Implications: The platform provides a potential framework for precision treatment of polymicrobial and multidrug-resistant sepsis, particularly when simultaneous infection control and prevention of inflammatory organ injury are required. Translation will require pharmacokinetic, toxicity, biodistribution, manufacturing, and large-animal studies before human trials.
Key Findings
- MICP@HG displayed peroxidase-like antibacterial activity and cuproptosis-like bacterial killing in acidic infectious microenvironments.
- As the microenvironment normalized, the nanozyme shifted toward superoxide dismutase- and catalase-like antioxidant and anti-inflammatory functions.
- The platform reduced systemic inflammation, preserved organ function, achieved complete survival in polymicrobial sepsis models, and conferred protection against reinfection through trained immunity.
Methodological Strengths
- The platform integrated imaging, catalytic therapy, targeted delivery, and immune modulation in a single construct.
- Therapeutic effects were evaluated across antimicrobial, inflammatory, organ-function, survival, and reinfection outcomes in polymicrobial sepsis models.
Limitations
- The evidence is based on preclinical sepsis models and does not establish efficacy or safety in humans.
- The abstract does not provide detailed information on sample sizes, randomization, blinding, dose optimization, or long-term toxicology.
Future Directions: Future studies should validate biodistribution, pharmacokinetics, immunological durability, resistance development, and organ-specific toxicity in large-animal models, followed by carefully designed first-in-human studies.
Sepsis remains a leading cause of mortality because current therapies fail to address its dynamically evolving pathophysiology, in which infection, oxidative stress, and immune dysfunction emerge sequentially and interdependently. Here, we present a pH-adaptive nanozyme platform (MICP@HG) that orchestrates stage-specific antibacterial and immunomodulatory activities throughout sepsis progression. The platform integrates near-infrared imaging, catalytic therapy, and immune regulation into a single construct. In acidic infectious microenvironments, the Cu-piceatannol shell exhibits peroxidase-mimicking activity and induces cuproptosis-like bacterial death through metabolic collapse and redox imbalance.
2. SIRT7-Mediated H2BK120 Succinylation Drives Aberrant Mitophagy in Sepsis-Associated Cognitive Dysfunction.
This study identifies a SIRT7–H2BK120 succinylation–PD-1/PD-L1–PINK1/Parkin pathway linking metabolic accumulation to aberrant neuronal mitophagy in sepsis-associated encephalopathy (SAE). Reduction of succinylation or inhibition of PD-1/PD-L1 signaling reduced neuronal injury and improved cognition, whereas neuron-specific Sirt7 deletion worsened the phenotype. SIRT7 overexpression reversed these pathological changes, supporting succinylation control as a therapeutic strategy.
Impact: The paper provides a coherent mechanistic link between sepsis-associated metabolic reprogramming, histone modification, immune checkpoint signaling, mitophagy, and cognitive dysfunction. It identifies SIRT7-dependent succinylation as a potentially targetable node in a complication with few disease-specific therapies.
Clinical Implications: The findings support investigation of succinylation-modulating or PD-1/PD-L1-directed strategies for SAE, but they do not justify clinical use. Because these pathways regulate host immunity and neuronal metabolism, safety, timing, cell specificity, and effects on infection control must be established before translation.
Key Findings
- Septic mice showed hippocampal succinate and succinyl-CoA accumulation with increased neuronal H2BK120 succinylation.
- H2BK120 succinylation at the Pdcd1 promoter activated the PD-1/PD-L1 axis and promoted PINK1/Parkin-dependent mitophagy, mitochondrial dysfunction, and neuronal apoptosis.
- SIRT7 overexpression reduced succinylation-associated pathology and improved cognitive dysfunction, whereas neuron-specific Sirt7 deletion exacerbated it.
Methodological Strengths
- The study combined pharmacological manipulation, neuron-specific genetic deletion, and SIRT7 overexpression to test pathway causality.
- Integrated CUT&Tag and transcriptomic analyses were linked to molecular, mitochondrial, neuronal, and behavioral outcomes.
Limitations
- The evidence is primarily derived from experimental mouse models and does not demonstrate that the pathway operates in human SAE.
- The safety and feasibility of manipulating SIRT7, histone succinylation, or PD-1/PD-L1 signaling during active infection remain unresolved.
Future Directions: Future work should validate the pathway in human brain or cerebrospinal-fluid samples, define the therapeutic window and cell specificity, and test whether pathway modulation preserves antimicrobial immunity while improving long-term neurological outcomes.
Sepsis-associated encephalopathy (SAE) is a severe neurological complication of sepsis, yet how metabolic disturbances engage epigenetic regulation in SAE remains unclear. We found that septic mice exhibited hippocampal succinate and succinyl-CoA accumulation, accompanied by enhanced neuronal histone H2BK120 succinylation (H2BK120su). Pharmacological reduction of succinylation alleviated neuronal injury and improved cognitive function. Mechanistically, integrated CUT&Tag and transcriptomic analyses identified Pdcd1 as a downstream gene associated with H2BK120su enrichment. H2BK120su enrichment at the Pdcd1 promoter activated the PD-1/PD-L1 axis, promoted mitochondrial translocation of PD-L1 and its interaction with PINK1, and triggered PINK1/Parkin-dependent mitophagy, leading to mitochondrial dysfunction and neuronal apoptosis.
3. Variability in Hospital-Onset Bacteremia in Ontario.
This population-based retrospective cohort study evaluated hospital-onset bacteremia and fungemia (HOB) across 114 acute-care hospitals in Ontario from 2017 to 2024. Among 3,325,900 admissions and 29,721,745 admission-days, 61,452 HOB episodes occurred, corresponding to 2.07 episodes per 1,000 admission-days. Rates ranged from 0.39 at the 10th percentile to 2.27 at the 90th percentile, and substantial between-hospital variation persisted after adjustment for patient and hospital characteristics.
Impact: The study provides large-scale empirical evidence that HOB can discriminate hospital performance, supporting its use as a potentially actionable health-care-associated infection quality metric. Its value is population-level and system-oriented rather than dependent on a single therapeutic intervention.
Clinical Implications: Hospitals and health systems may use standardized HOB surveillance to identify sites requiring infection-prevention review, compare care processes, and monitor quality-improvement interventions. Before benchmarking or public reporting, harmonized definitions, ascertainment practices, case-mix adjustment, and validation against preventability are needed.
Key Findings
- Across 114 Ontario acute-care hospitals, 61,452 HOB episodes occurred during 3,325,900 admissions and 29,721,745 admission-days.
- The overall HOB rate was 2.07 episodes per 1,000 admission-days, with hospital rates ranging from 0.39 at the 10th percentile to 2.27 at the 90th percentile.
- After adjustment for patient and hospital characteristics, the hospital-level random-intercept standard deviation was 0.36, corresponding to a rate ratio of 1.43 per 1 standard deviation.
Methodological Strengths
- The study used population-based administrative and clinical databases covering more than 3.3 million admissions across 114 hospitals.
- Generalized linear mixed-effects modeling accounted for patient and hospital characteristics while quantifying residual hospital-level variation.
Limitations
- The retrospective observational design cannot establish that between-hospital differences are caused by modifiable care processes.
- HOB definition based on a positive blood culture on or after hospital day 4 may be affected by blood-culture practices, contamination, referral patterns, and differences in case mix not fully captured by adjustment.
Future Directions: Future studies should test the reliability of HOB across jurisdictions, determine the preventable fraction, evaluate links with specific infection-prevention practices, and assess whether feedback-driven interventions reduce HOB rates without incentivizing changes in testing behavior.
IMPORTANCE: Hospital-onset bacteremia and fungemia (HOB) is being proposed as a new hospital quality metric for health care-associated infections. There is a lack of data on the ability of HOB to discriminate between hospitals from a large regional perspective. OBJECTIVE: To describe and compare the HOB rates across hospitals for the province of Ontario in Canada. DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study used ICES Ontario databases. Participants were adult patients admitted to an acute care hospital from 2017 to 2024 in Ontario, Canada. EXPOSURE: Local care processes and practices in different hospitals. MAIN OUTCOMES AND MEASURES: HOB was defined as a positive blood culture collected on or after hospital day 4. HOB rates per admission-days were described across hospital sites. A generalized linear mixed-effects model was used to compare variation in HOB rates across hospitals while adjusting for patient and hospital characteristics.